Announcement PDF ASX Announcement Percheron Therapeutics Limited ABN 41 095 060 745 ASX: PER | FSE: AWY | US OTC: ATHJY RESULTS OF ANNUAL GENERAL MEETING Melbourne, Australia – 7 October 2026: Percheron Therapeutics Limited (ASX:PER or “the Company”) is pleased to advise the results of today’s Annual General Meeting of shareholders. In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act, the results of the Annual General Meeting are set out in the attached report and include a summary of the poll voting results by proxies on each resolution considered at the Annual General Meeting. All resolutions to be voted on at the meeting were decided on a poll. The Board thanks shareholders for their attendance and participation at the 2026 Annual General Meeting. About Percheron Therapeutics Limited Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focusedon thedevelopment and commercialisationofnoveltherapiesfor oncology and rare diseases. The company’s lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated, and Percheron aims to commence further clinical trials in CY2026. For further information, please see our website at www.PercheronTx.com, or email info@PercheronTx.com. This announcement has been authorised for release to the Australian Securities Exchange by the Board of Directors. The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2. Resolution Result If s250U applies Resolution Resolution Type For Against Proxy's Discretion Abstain For Against Abstain* Carried / Not Carried 206,896,580 2,665,799 5,531,903 250 212,428,483 2,665,799 250 96.19% 1.24% 2.57% 98.76% 1.24% 282,694,179 1,895,617 5,531,903 525,333 288,226,082 1,895,617 525,333 97.44% 0.65% 1.91% 99.35% 0.65% 206,571,390 4,491,265 4,031,877 0 210,603,267 4,491,265 0 96.04% 2.09% 1.87% 97.91% 2.09% 282,742,890 3,872,265 4,031,877 0 286,774,767 3,872,265 0 97.28% 1.33% 1.39% 98.67% 1.33% 282,727,890 3,887,265 4,031,877 0 286,759,767 3,887,265 0 97.28% 1.34% 1.39% 98.66% 1.34% 206,892,830 2,569,799 4,131,877 2,152,526 211,024,707 2,569,799 2,152,526 96.86% 1.20% 1.93% 98.80% 1.20% 206,348,593 3,114,036 4,131,877 2,152,526 210,330,470 3,114,036 2,152,526 96.61% 1.46% 1.93% 98.54% 1.46% 282,100,104 4,105,265 4,441,663 0 286,541,767 4,105,265 0 97.06% 1.41% 1.53% 98.59% 1.41% 282,115,104 4,052,765 4,441,663 37,500 286,556,767 4,052,765 37,500 97.08% 1.39% 1.53% 98.61% 1.39% 9(a). Ratification of prior issue of Tranche 1 Placement Shares issued under Listing Rule 7.1 Ordinary Carried N/A 7. Approval of potential termination benefits under the ESOP Ordinary Carried N/A 8. Approval of 10% Placement Capacity (Special Resolution) Special Carried N/A 5. Ratification of Prior Issue of Joint Lead Manager Options to Blue Ocean and Cygnet Capital Ordinary Carried N/A 6. Re-approval of Percheron Therapeutics Employee Share Option Plan Ordinary Carried N/A 3. Approval for issue of Restricted Stock Units to Dr Michael Baker Ordinary Carried N/A 4. Ratification of Prior Issue of Adviser Options to Blue Ocean Ordinary Carried N/A 1. To Adopt the 2026 Remuneration Report Ordinary Carried N/A 2. Election of Director - Dr James Garner Ordinary Carried N/A Percheron Therapeutics Limited Annual General Meeting Wednesday, 07 October 2026 Results of Meeting Resolution details Instructions given to validly appointed proxies (as at proxy close) Number of votes cast on the poll (where applicable) 282,115,104 4,052,765 4,441,663 37,500 286,556,767 4,052,765 37,500 97.08% 1.39% 1.53% 98.61% 1.39% 282,100,104 4,105,265 4,441,663 0 286,541,767 4,105,265 0 97.06% 1.41% 1.53% 98.59% 1.41% 281,742,658 4,105,265 4,799,109 0 286,541,767 4,105,265 0 96.94% 1.41% 1.65% 98.59% 1.41% 284,469,652 4,105,265 1,714,669 357,446 286,184,321 4,105,265 357,446 98.00% 1.41% 0.59% 98.59% 1.41% 284,444,319 4,105,265 1,514,669 582,779 285,958,988 4,105,265 582,779 98.06% 1.42% 0.52% 98.58% 1.42% 282,099,854 4,105,265 4,441,663 250 286,541,517 4,105,265 250 97.06% 1.41% 1.53% 98.59% 1.41% * Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. 13. Approval of Issue of Broker Options to Blue Ocean and Cygnet Capital Ordinary Carried N/A 12(a). Approval for issue of Related Party Placement Securities to Dr Michael Baker Ordinary Carried N/A 12(b). Approval for issue of Related Party Placement Securities to Mr James Baker Ordinary Carried N/A 10. Approval for issue of Tranche 2 Placement Shares Ordinary Carried N/A 11. Approval for issue of Placement Options Ordinary Carried N/A 9(b). Ratification of prior issue of Tranche 1 Placement Shares issued under Listing Rule 7.1A Ordinary Carried N/A